# Hypertension (HTN) 

Daniel Motta-Calderon

---

## Background

- Elevated systolic blood pressure and diastolic blood pressure are
    associated with increased cardiovascular disease (CVD) risk

- HTN is the most prevalent modifiable risk factor for premature CVD

## Definitions

- ACC/AHA definition of HTN: taking antihypertensive medication or
    having a systolic pressure ≥130 mmHg and/or a diastolic pressure ≥80
    mmHg

- Resistant HTN**:** Uncontrolled BP despite taking 3 antihypertensive
    medications including a diuretic OR 4 total medications

- Whitecoat HTN: Mean BPs lower than threshold of HTN based on
    out-of-office measurements (falsely elevated measurements during
    visits). If SBP \> 130 but \< 160, consider screening for white coat
    HTN with home monitoring

- Masked HTN: Mean BP at/above threshold for hypertension based upon
    out-of-office measurements (falsely decreased measurements during
    visits). If office SBPs consistently 120-129, consider screening for
    masked HTN with home monitoring

## Screening

- Grade A USPTF rec: Screen all adults \>18. Screen adults at least
    semiannually if have risk factors for HTN (obesity, AA), or if
    previously measured SBP 120-129

## Diagnosis

- Proper BP measurement:  legs uncrossed, supported arm at level of
    heart, after 5 minutes of rest and with empty bladder; avoid
    caffeine or tobacco 30 minutes prior

- Ideally, primary detection in clinical setting (BP ≥130/80) followed
    by confirmation with ambulatory blood pressure monitoring (ABPM): 

    - 24hrs mean of systolic ≥125 or diastolic ≥75mmHg 

    - Daytime mean systolic ≥130mmHg or diastolic ≥80mmHg  

    - Nighttime mean systolic ≥110 mmHg or ≥65 diastolic mmHg 

- If ABPM not possible, 2-3 outpatient measurements at 1-4 week
    intervals are required to confirm diagnosis  

- BP \>160/100mmHg in the outpatient setting with evidence of
    end-organ damage (ischemic CMP, CVA, hypertensive retinopathy, LV
    hypertrophy, CKD) 

- Any patient presenting with hypertensive emergency or severe
    asymptomatic hypertension (\>180/120mmHg) 

## Evaluation

- Assess target organ damage as pertinent: CVA, retinopathy, LV
    hypertrophy/dysfunction, HF, CAD, CKD, PAD.  

    - BMP, CBC, lipid panel, UA, TSH, EKG. Consider additional testing
        including TTE, urine Alb:Cr ratio, or uric acid, ABI 

    - Calculate ACSVD 10y risk

- Distinguish between primary (90% incidence) and secondary HTN
    (10%): 

    - Suspect 1º if gradual onset, family hx, associated with weight gain
        & lifestyle factors 

    - Suspect 2º if drug-resistant, abrupt onset, onset \<30yo,
        exacerbation of previously controlled HTN, onset of diastolic
        hypertension in older adults \>65yo, unprovoked or excessive
        hypokalemia

| **Common 2<sup>o</sup> Causes**                                                                                                                                                       | **Suggestive Features**                                      | **Diagnostic Testing**                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------|
| Primary Kidney Disease                                                                                                                                                                | Hypervolemia, ↑ Cr, abnormal UA, family history of PKD       | UA, Urine Alb:Cr ratio, Renal US                        |
| Renovascular disease (RAS or FMD)                                                                                                                                                     | Renal bruit, ↑ Cr after ACE-I or ARB, young age              | Doppler renal US                                        |
| OSA                                                                                                                                                                                   | Apneic events, somnolence, obesity                           | Polysomnography                                         |
| Primary Hyperaldosteronism                                                                                                                                                            | Hypokalemia, metabolic alkalosis, resistant HTN, etc.        | Start with plasma aldosterone/renin levels              |
| Drug or Alcohol Induced                                                                                                                                                               | H/o substance use (cocaine, caffeine, nicotine, medications) | UDS, BP improvement after withdrawal of suspected agent |
| Uncommon 2<sup>o</sup> causes: Pheochromocytoma, Cushing’s syndrome, thyroid dysfunction, aortic coarctation, primary hyperparathyroidism, acromegaly, congenital adrenal hyperplasia |                                                              |                                                         |

## Management

| ACA-AHA guidelines (2017) (based on SPRINT trial) |                                               |                                                                                                                                   |
|---------------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Elevated BP                                       | systolic 120-129 mmHg AND diastolic \<80 mmHg | Non-pharmacological interventions and reassess in 3-6 months                                                                      |
| Stage 1                                           | systolic 130-139 mmHg OR diastolic 80-89 mmHg | If 10-y CVD risk ≥10%, non-pharm intervention + BP-lowering medication. Reassess monthly until BP goal met, then every 3-6 months |
| Stage 2                                           | systolic ≥140 mmHg OR diastolic ≥90 mmHg      | Non-pharmacological intervention + BP lowering medication. Reassess monthly until BP goal met, then every 3-6 months              |

## Non-pharmacological interventions: regardless of stage  

- 8-14 mmHg ↓: DASH diet (fresh produce, whole grains, low-fat dairy) 

- 5-10 mmHg ↓: Weight loss (10 kg or 22 lbs), expect 1mm Hg for every
    1kg reduction in body weight 

- 3-9 mmHg ↓: Na+ restriction (1.5 g / day), aerobic exercise for
    90-150 min/week, increased intake of K+ rich foods 

- 2-4 mmHg ↓: Moderate EtOH (2 drinks/day for men; 1 drink/day for
    women) 

- Consider deprescribing or switching amphetamines, antidepressants
    (MAOi, SNRIs, TCAs), atypical antipsychotics (clozapine,
    olanzapine), caffeine, decongestants (phenylephrine,
    pseudoephedrine), cyclosporine, oral contraceptives, NSAIDs,
    steroids

## Pharmacologic therapy 

- Three main classes of drugs use for initial monotherapy for primary
    hypertension include: ACE-Is/ARBs, CCBs (most frequently a
    dihydropyridine), and thiazide diuretics

- Note that there is wide variability among patients as some will
    respond to one antihypertensive drug but not another

- Black patients often respond best to CCBs or thiazides

- Individualize therapy depending on comorbidities

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 40%" />
<col style="width: 40%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Drug Class</strong> </th>
<th><strong>Common Drugs</strong> </th>
<th><strong>Side effects/ comments</strong> </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Thiazide diuretics</strong> </td>
<td>HCTZ 12.5-50 mg  <br />
Chlorthalidone 12.5-25 mg: preferred agent based on RCT evidence though
inc risk electrolyte abnormalities</td>
<td><p>HypoNa, HypoMg, HypoK, increased uric acid, hypovolemia, </p>
<p>Orthostatic hypotension </p></td>
</tr>
<tr class="even">
<td><strong>ACE-I</strong> </td>
<td><p>Lisinopril, benazepril, fosinopril, quinapril (all 5-40 mg
daily)</p>
<p>Ramipril, 2.5-20 mg in 1-2 doses </p></td>
<td>Angioedema (more common in AA) AKI, hyperkalemia, cough </td>
</tr>
<tr class="odd">
<td><strong>ARBs</strong> </td>
<td><p>Losartan 25-100 mg in 1-2 doses </p>
<p>Candesartan 8-32 mg in 1-2 doses </p>
<p>Irbesartan 150-300 mg <br />
Valsartan 80-320 mg </p></td>
<td>AKI, hyperkalemia <br />
Angioedema (less frequent than ACE-I) </td>
</tr>
<tr class="even">
<td><strong>CCB</strong> </td>
<td><p>Dihydropyridine: <br />
Amlodipine 2.5-10 mg 1-2 doses Nifedipine 30-120 mg in 1-2 doses </p>
<p>Nondihydropyridine: </p>
<p>Diltiazem ER 120-480 mg Verapamil ER 100-480 mg </p></td>
<td><p>Dihydropyridine:  <br />
Peripheral edema  <br />
Worsening proteinuria </p>
<p> Nondihydropyridine:  <br />
Constipation <br />
Heart block if used with BB  <br />
Contraindicated in HFrEF </p></td>
</tr>
<tr class="odd">
<td><strong>Aldosterone receptor antagonists</strong> </td>
<td>Spironolactone 12.5-50 mg  <br />
Eplerenone 25-50 mg </td>
<td><p>Good choice for resistant HTN </p>
<p>AKI, hyperkalemia <br />
Spironolactone—gynecomastia &amp; sexual side effects </p></td>
</tr>
<tr class="even">
<td><strong>BB</strong> </td>
<td>Carvedilol 6.25-25 mg bid  <br />
Metoprolol succinate 25-200 mg qd <br />
Nebivolol 5-10 mg <br />
Labetalol 100-300 bid </td>
<td>Reserve for CHF/CAD  <br />
Hyperglycemia, fatigue, ↓ HR <br />
β 1-selective may be safer in pts with COPD, asthma, diabetes </td>
</tr>
<tr class="odd">
<td><strong>Vasodilators</strong> </td>
<td>Hydralazine 25-100 mg bid or tid Minoxidil 5-10 mg </td>
<td>Reflex tachycardia, fluid retention </td>
</tr>
<tr class="even">
<td><strong>Centrally- acting agents (alpha 2 agonists)</strong> </td>
<td><p>Clonidine 0.1-0.2 qd, (Weekly transdermal patch is preferred to
avoid non- compliance and subsequent reflex HTN) </p>
<p>Methyldopa 250-500 mg qd </p></td>
<td>Rebound hypertension, withdrawal -Reserved for resistant
hypertension due to unfavorable side effect profile </td>
</tr>
</tbody>
</table>

| **Conditions **              | **Drug Class **                                               |
|------------------------------|---------------------------------------------------------------|
| Heart failure                | ACE-I/ARB or ARNI + BB + spironolactone + diuretics           |
| CAD                          | ACE-I or BB                                                   |
| Diabetes                     | All first line agents, ACE-I/ARB if presence of albuminuria   |
| CKD                          | ACE-I/ARB                                                     |
| Recurrent stroke prevention  | ACE-I, thiazide diuretic                                      |

If not meeting goals, combination therapy \> doubling single agent (more
effective, less side effects) 

- Preferred combinations 

    - ACEi/ARB + CCB 

    - ACEi/ARB + CCB + thiazide. 

    - ACEi/ARB + CCB + MRA 

    - Do not combine beta-blockers with non-dihydropyridines. 

     Therapy goals 

    - General population: \<130/80mmHg 

    - Frail patients with orthostatic hypotension, limited life
        expectancy: consider less aggressive goal \<140/90 

## Additional Information

- VA Specific Guidance:
    https://www.healthquality.va.gov/guidelines/CD/htn/

- Agents that require PADR:

    - ACEIs - Quinapril

    - ARBs – Candesartan, Irbesartan, Olmesartan, Telmisartan

    - Beta blockers – Labetalol, Nebivolol

    - DHP – Nifedipine SA

    - Aldosterone Receptor Antagonist – Eplerenone

    - Alpha2 Agonist – Clonidine patch

- How to get BP cuff at the VA

    - Prosthetics consult BP Cuff TVHS. \*Must answer all questions in the
        consult, including blood pressure cuff size

## Low-cost options

- Publix: Free (amlodipine, lisinopril), $7.50 x 90 days (losartan,
    metoprolol tartrate, HCTZ)

- Walmart: $4/month (amlodipine, carvedilol, enalapril, hydralazine,
    HCTZ, irbesartan, lisinopril, losartan, ramipril)
